ORPHAGEN PARTNER, JAPAN TOBACCO, INITIATES A PHASE I CLINICAL TRIAL OF A NOVEL SMALL MOLECULE THERAPEUTIC FOR AUTOIMMUNE AND ALLERGIC DISEASES

...

Orphagen Pharmaceuticals Presents Pharmacology of ROR-beta Antagonists at the Keystone Symposium on Nuclear Receptors

...

Orphagen Pharmaceuticals Awarded Federal Funding to Investigate a Novel Drug Discovery Target for Sickle Cell Disease

...

Orphagen Pharmaceuticals Awarded $224,954 to Investigate an Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy

...

Recent News

News Archives